This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias (HIP)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2007 by Harbinger Medical, Inc..
Recruitment status was:  Active, not recruiting
Information provided by:
Harbinger Medical, Inc. Identifier:
First received: November 20, 2007
Last updated: NA
Last verified: November 2007
History: No changes posted
The purpose of this study is to determine how well the device predicts susceptability to potentially lethal ventricular arrhythmias.

Sudden Cardiac Death

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Harbinger ICD Patient (HIP) Study

Further study details as provided by Harbinger Medical, Inc.:

Primary Outcome Measures:
  • Life Threatening Cardiac Event (death or annotated malignant ventricular arrhythmia detected by ICD and confirmed by cardiologist review) [ Time Frame: Up to two years ]

Enrollment: 320
Study Start Date: September 2003
Estimated Study Completion Date: October 2009
Post myocardial infarction patients who received an ICD, stratified into low versus high WMI groups

Detailed Description:

Sudden cardiac death (SCD) accounts for half of all deaths from cardiovascular causes, with an annual incidence of 1 to 2 deaths per 1000 population. In the United States this translates to between 300,000 to more than 400,000 deaths annually. Results from numerous large, well designed clinical trials have demonstrated the efficacy of the implantable cardioverter-defibrillator (ICD) for improving survival in patients with ischemic heart disease. However, measures used to risk stratify patients, such as left ventricular ejection fraction do not adequately identify those patients who can most benefit from ICD therapy. As a result, many patients who currently receive an ICD do not use the device. In addition, many more patients who could benefit from ICD therapy are outside of current guidelines and do not have access to this life-saving therapy.

This prospective study was intended to determine how well the Harbinger Wedensky Modulation Index (WMI) technique risk stratifies patients into two groups: those needing antiarrhythmic therapy and those who do not need antiarrhythmic therapy.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Post myocardial infarction patients who received an ICD are included. Enrollment is at eight sites - four in the USA and four in three European countries. The enrollment sites are hospitals and teaching institutions.

Inclusion Criteria:

  • Post myocardial infarction patients receiving ICD therapy

Exclusion Criteria:

  • Patients unable to give consent
  • Pacemaker dependant patients
  • Pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00562757

United States, Arizona
Arizona Arrhythmia Consultants
Phoenix, Arizona, United States, 85251
United States, Kansas
Galichia Heart Hospital
Wichita, Kansas, United States, 67220
United States, Massachusetts
Caritas St. Elizabeth's Hospital
Boston, Massachusetts, United States, 02135
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55902
University of Bonn
Bonn, Germany, D-53105
University of Mannheim
Mannheim, Germany, 68167
Oslo, Norway, 0027
Kantonsspital Luzern
Luzern, Switzerland, CH-6000
Sponsors and Collaborators
Harbinger Medical, Inc.
Study Director: Harold Hoium, MBA Harbinger Medical, Inc.
  More Information Identifier: NCT00562757     History of Changes
Other Study ID Numbers: HMI-HIP
Study First Received: November 20, 2007
Last Updated: November 20, 2007

Keywords provided by Harbinger Medical, Inc.:
Wedensky modulation
Risk stratification
Ischemic heart disease
ICD guidelines
Myocardial infarction

Additional relevant MeSH terms:
Death, Sudden, Cardiac
Pathologic Processes
Heart Arrest
Heart Diseases
Cardiovascular Diseases
Death, Sudden processed this record on August 23, 2017